EGFR and cancer: Lapatinib’s cancer targets are ErbB1 (EGFR) (IC50 = 5.3 nM) and ErbB2 (HER2) (IC50 = 35 nM) (21), yet it was shown to comparably bind the ATP binding site of ErbB4 (22).